Alain Hendlisz

Scopus Publications

Deep epigastric lymph node involvement in patients with ovarian and colorectal peritoneal metastasis: A prospective pilot study
Antoine El Asmar, Charif Khaled, Isabelle Veys, Maria Galdon Gomez, Laurine Verset, et al.
Surgery United States, 2026
Real-World Outcomes of [177Lu]Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors: Data from a Belgian ENETS Center of Excellence
I Lazarenko, M Mileva, R Manta, P Kristanto, A Hendlisz, et al.
Acta Gastro Enterologica Belgica, 2026
Background and study aims: Peptide receptor radionuclide therapy (PRRT) has been reimbursed in Belgium since 2022. Post marketing monitoring of efficacy in Belgian context has not yet been performed. This study aimed to evaluate the efficacy and safety of PRRT in patients with progressive metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients and methods: Our retrospective analysis included GEP-NET patients who received at least one cycle of [177Lu] Lu-DOTA-TATE at Institute Jules Bordet (Brussels, Belgium) between 2013 and 2023. Treatment response was assessed according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis. Treatment safety profiles were reported descriptively. Results: Following initial PRRT (PRRT-1), in 110 patients with progressive metastatic GEP-NETs (grades 1-3), median PFS was 22.5 months (95% CI: 19.7–29), and median OS was 42.3 months (95% CI: 34.3–55). RECIST 1.1 responses were complete response in 1%, partial response in 21.6%, stable disease in 60.8%, and progression in 16.7% of patients. Median time of follow-up post PRRT-1 was 26.4 months (range: 0.8 – 106.4). Grade 3-4 anemia, leukopenia, lymphopenia and thrombocytopenia occurred in 1.9%, 2.8%, 50.5% and 2.8% of patients, respectively. Two patients (1.8%) developed myelodysplastic syndrome. Grade 3 or 4 renal toxicity was observed in two patients who had impaired renal function prior to PRRT. Conclusion: Post-marketing analysis in an ENETS Center of Excellence confirmed that the efficacy and safety of PRRT in GEPNETs are consistent with phase 3 trial data.
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Ming Lei, Michael J. Overman, Jin Yao, Thierry André, Sara Lonardi, et al.
Nature Communications, 2025
Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?
Michel Meyers, Ioannis Karfis, Alain Hendlisz
Current Opinion in Oncology, 2025
Purpose of review The purpose of this review is to evaluate the role of epigenetic-targeting approaches in the management of neuroendocrine neoplasms (NENs), particularly as a priming strategy for subsequent therapies. We explore the molecular basis of epigenetic modifications in NENs, and we review preclinical and clinical studies on DNA methyltransferase and histone deacetylase (HDAC) inhibitors. Recent findings DNA methyltransferase and HDAC inhibitors can upregulate SSTR2 expression, thereby improving radioligand uptake and treatment response in NENs. The LANTana study investigates ASTX727 as a strategy to restore SSTR2 expression in metastatic NENs, allowing previously ineligible patients to receive PRRT. Preclinical studies demonstrate that combining epigenetic agents with radiotherapy, chemotherapy, or targeted inhibitors can enhance tumour sensitivity and overcome resistance. Summary Epigenetic modifications play a crucial role in NENs, influencing tumour progression, therapy resistance, and SSTR2 expression. Epigenetic priming with DNA methyltransferase and HDAC inhibitors can enhance SSTR2 expression, improving the efficacy of PRRT in NENs. The LANTana study and other trials are investigating whether epigenetic-targeting approaches can be integrated into NEN treatment to optimize PRRT and overcome therapeutic limitations.
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J. Taieb, J. Seligmann, D. Modest, C. Girault, F. Rivera, et al.
ESMO Open, 2025
Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer
Zelda Paquier, Jennifer Dhont, Thomas Guiot, Hugo Levillain, Gabriela Critchi, et al.
JCO Clinical Cancer Informatics, 2025
PURPOSE Managing chemorefractory metastatic colorectal cancer (mCRC) requires a meticulous equilibrium between the efficacy and toxicity of interventions, a task compounded by the constrained life expectancy of the patient. While existing prognostic tools, such as the Colon Life nomogram, primarily focus on general patient conditions or a single diagnostic modality, they do not fully integrate the potential predictive value of multimodal data. This study aims to develop and validate an Imaging Score, integrating clinical and imaging features derived from whole-body 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET-CT), predicting death probability within 12 weeks from treatment initiation for refractory disease. MATERIALS AND METHODS The development cohort comprises 254 patients from three clinical trials. Nine clinical variables and six imaging variables were assessed. After optimal subset selection through recursive Feature Elimination with cross-validation, a support vector classifier-trained machine learning model generated the Imaging Score. Validation was performed on a real-life patient cohort (n = 74). Model performance was assessed on discrimination (Harrell C-index) and calibration. RESULTS Final prognostic features included whole-body metabolically active tumor volume, Eastern Cooperative Oncology Group performance status, visceral fat density, number of metastatic sites, body mass index, maximum standardized distance, and months since diagnosis. The Imaging Score demonstrated robust discriminative ability in both the development (C-index, 0.797) and validation (C-index, 0.714) sets, outperforming the Colon Life nomogram that tended to overestimate 12-week mortality. CONCLUSION The Imaging Score, integrating 18 F-FDG PET-CT imaging with clinical parameters, is an effective prognostic tool for patients with chemorefractory mCRC. This combination of imaging biomarkers with clinical factors improves discrimination, enhancing its potential for clinical decision making, patient stratification for chemorefractory treatments, and trial eligibility.
Management of high-grade neuroendocrine neoplasms: impact of functional imaging
O Islam, K Sarti, L Verbruggen, V Vandersmissen, K Vanden Bulcke, et al.
Endocrine Related Cancer, 2025
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO subdivided the grade 3 (G3) neuroendocrine neoplasms (NEN) characterised by Ki-67 > 20% into the well-differentiated G3 neuroendocrine tumour (NET) and G3 poorly differentiated neuroendocrine carcinoma (NEC) subgroups. Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain. Therefore, we initiated a real-world retrospective observational cohort study using data from 225 NEC and 58 NET G3 patients treated in Belgium. Analysis of patient and tumour characteristics and the effect of survival was conducted. Most frequent primary locations were pancreatic (32.9%) and colorectal (21.5%), and 71.8% was diagnosed with stage IV disease. Median overall survival (mOS) was higher in NET G3 (41.3 months (m)) compared to NEC (13.2m). Of those who underwent functional imaging, fluorodeoxyglucose–positron emission tomography (18F-FDG-PET) imaging was positive in 90.6 and 95.6% of the NET G3 and NEC patients, respectively, and somatostatin receptor (SSTR) expression was seen in 97.4 and 66.0%, respectively. The latter was linked to better mOS, suggesting the added value of performing both SSTR imaging and 18F-FDG-PET for high-grade (HG) NEN to provide prognostic information and to possibly expand therapeutic options, which are currently reserved for lower-grade NEN patients. Moreover, while debated, in our population, primary surgery was performed in 92 and 73.5% of locoregional NET G3 and NEC cases, respectively, indicating that surgery can be considered in locoregional setting. Finally, platinum–etoposide was the predominant first-line treatment in metastatic NEC, with no significant survival difference between carboplatin and cisplatin.
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
Irene Assaf, Giacomo Bregni, Geraldine Anthoine, Thomas Aparicio, Pascal Artru, et al.
Clinical Colorectal Cancer, 2025
Surgical management of pseudomyxoma peritonei: low-volume center experience
Charif Khaled, Lina Safar, Alain Hendlisz, Maria Gomez Galdon, Paulus Kristanto, et al.
Acta Chirurgica Belgica, 2025
INTRODUCTION Pseudomyxoma peritonei (PMP) is a rare disease characterized by diffuse peritoneal invasion of multifocal mucinous deposits. Gold standard treatment involves cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). We aimed to compare the outcomes of operated PMP patients in a low-volume center, with those of high-volume centers and using other regimens. MATERIALS AND METHODS Retrospective analysis was conducted for PMP patients treated by CRS + HIPEC (using the Elias high-dose Oxaliplatin HIPEC regimen) over a 15-year period (January 2007 - December 2021) at the Jules Bordet Institute - H.U.B. RESULTS 32 patients were included. Pathology results were: 21.9% acellular mucin, 34.4% low-grade, and 43.7% high-grade. The median peritoneal cancer index was 24 (range 3-36). The median follow-up was 58 months. The rate of major complications (Clavien-Dindo III/IV) was 41% and postoperative mortality was 3%. Mean disease-free survival (DFS) was estimated at 40 +/- 4 months (standard deviation (SD)) while overall survival (OS) was 122 +/- 9 months (SD). DFS reached a plateau of 44.5% at 5 and 10 years and OS was 92.3% and 76.2% respectively. Statistical analysis showed low-grade PMP to be predictive of better DFS and OS (p = 0.0111 and p = 0.0293 respectively). We also found that female gender was predictive of better DFS (p = 0.0262). CONCLUSION Our postoperative morbidity and mortality rates, DFS, and OS were similar to those reported in the literature for high-volume PMP centers. Our theory is that surgical proficiency can be more attributed to the surgeon's CRS experience, regardless of the nature of the disease.
Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids
Giulia Agostini, Morgane Leprovots, Jérôme Jeandriens, Anne Lefort, Frédérick Libert, et al.
Frontiers in Cell and Developmental Biology, 2025
Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide, with its incidence continuing to rise. Regorafenib, a multi-kinase inhibitor approved for palliative treatment, has been shown to extend survival in patients with metastatic CRC (mCRC) who have failed standard therapies. However, its clinical benefit is limited to a subset of patients, is typically short-lived, and is often accompanied by significant toxicity. The mechanisms by which CRC cells develop resistance to regorafenib remain incompletely understood. In this study, we investigated the mechanisms of regorafenib resistance using a preclinical mouse colon organoid model. Transcriptomic analysis of Apc wild-type and Apc-deficient organoids treated with regorafenib revealed upregulation of epithelial-to-mesenchymal transition (EMT), alterations in the secretome, and increased activation of phosphorylated Erk1/2. Notably, co-treatment with an autophagy inhibitor suppressed regorafenib-induced EMT and its associated secretory phenotype, leading to reduced cell proliferation and enhanced apoptosis in mouse organoids. The efficacy of this drug combination was further supported by cell viability assays in human CRC cell lines. In contrast, primary mouse colon fibroblasts exhibited greater resistance to both single-agent and combination regorafenib treatments. In summary, our findings using an organoid model suggest that autophagy inhibition may represent a promising strategy to overcome chemoresistance to regorafenib in mCRC patients.
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, Paulus Kristanto, Wendy Delbart, et al.
Ejnmmi Research, 2024
Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy
Rafael Caparica, Larissa Amorim, Paulo Amaral, Lucas Uratani, David Muniz, et al.
BMJ Supportive and Palliative Care, 2024
Ectopic ACTH-Dependent Cushing's Syndrome Emerging at a Late Stage of a Mixed Histology Neuroendocrine Neoplasm: A Case Report
Michel Meyers, Ahmad Awada, Ioannis Karfis, Daphné t&apos, Kint de Roodenbeke, et al.
Case Reports in Oncology, 2024
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Data From the Prospective Phase 2 LUMEN Study
Magdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, Rachele Danieli, Carlos Artigas, et al.
Clinical Nuclear Medicine, 2024
Beyond 'the good, the bad and the ugly': let us put rectal cancer patients at the centre of the decision making
Francesco Sclafani, Chiara Conti, Chiara Gallio, Alain Hendlisz
Current Opinion in Oncology, 2024
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies
Charlotte Hanssens, Oumnia Mouna, Michel Meyers, Alain Hendlisz
Current Opinion in Oncology, 2024
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
Roberta Fazio, Alessandro Audisio, Valentina Daprà, Chiara Conti, Nada Benhima, et al.
Cancer Treatment Reviews, 2024
PD-L1 Expression in Paired Samples of Rectal Cancer
Mina Coussement, Roberta Fazio, Alessandro Audisio, Reem El Khoury, Fatima-Zahra Abbassi, et al.
Cancers, 2024
Current trends of clinical trials for older patients with cancer: A systematic review.
Roberta Fazio, Alessandro Audisio, Everardo D. Saad, Giacomo Bregni, Daniel Genel Sur, et al.
Journal of Clinical Oncology, 2024
Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study
Ayoub Mokhtari, Roberto Casale, Zohaib Salahuddin, Zelda Paquier, Thomas Guiot, et al.
Diagnostics, 2024
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, et al.
Journal of Nuclear Medicine, 2024
Neoadjuvant chemotherapy for early-stage colon cancer
Alessandro Audisio, Roberta Fazio, Valentina Daprà, Irene Assaf, Alain Hendlisz, et al.
Cancer Treatment Reviews, 2024
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with micro-satellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Heinz-Josef Lenz, Michael J. Overman, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, et al.
Journal of Clinical Oncology, 2024
Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
Irene Assaf, Danai Fimereli, Geraldine Anthoine, Roberta Fazio, Valentina Daprà, et al.
Cancers, 2023
Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer
Ali Bohlok, Camille Tonneau, Sophie Vankerckhove, Ligia Craciun, Valerio Lucidi, et al.
Clinical and Experimental Metastasis, 2023
Immunotherapies in non-metastatic gastrointestinal cancers
Rita Saúde-Conde, Dan Nguyen, Alain Hendlisz
Current Opinion in Oncology, 2023
Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back?
Alessandro Audisio, Roberta Fazio, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2023
Editorial introductions
Current Opinion in Oncology, 2023
The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study
Antoine El Asmar, Pieter Demetter, Fahd Fares, Francesco Sclafani, Alain Hendlisz, et al.
Annals of Surgical Oncology, 2023
Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review
Giacomo Bregni, Elena Trevisi, Rita Saúde Conde, Michele Vanhooren, Tugba Akin Telli, et al.
Journal of the National Cancer Institute, 2023
Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases
Ali Bohlok, Lisa Inchiostro, Valerio Lucidi, Sophie Vankerckhove, Alain Hendlisz, et al.
European Journal of Surgical Oncology, 2023
Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers
Ali Bohlok, François Richard, Valerio Lucidi, Antoine El Asmar, Pieter Demetter, et al.
Frontiers in Oncology, 2023
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
Tugba Akin Telli, Giacomo Bregni, Michele Vanhooren, Rita Saude Conde, Alain Hendlisz, et al.
Cancer Treatment Reviews, 2022
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
Pashalina Kehagias, Nadège Kindt, Mohammad Krayem, Ahmad Najem, Giulia Agostini, et al.
Cells, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
T. André, S. Lonardi, K.Y.M. Wong, H.-J. Lenz, F. Gelsomino, et al.
Annals of Oncology, 2022
Editorial: 'All you need is immunotherapy': A new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2022
Mind the target: Human epidermal growth factor receptor 2 in colorectal cancer
Rita Saúde-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2022
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer
Erwin Woff, Lisa Salvatore, Federica Marmorino, Dario Genovesi, Gabriela Critchi, et al.
Journal of Nuclear Medicine, 2022
JCOG0603: Are We Really Sure This Was a Negative Trial?
Rita Saude Conde, Giacomo Bregni, Everardo Saad, Alain Hendlisz, Francesco Sclafani
Journal of Clinical Oncology, 2022
Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
P.J. Ross, H.S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, et al.
ESMO Open, 2022
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, et al.
Journal of Clinical Oncology, 2022
Circulating DNA in the neoadjuvant setting of early stage colon cancer
Giacomo Bregni, Andrea Pretta, Chiara Senti, Elena Acedo Reina, Caroline Vandeputte, et al.
Acta Oncologica, 2022
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial
Caroline Vandeputte, Giacomo Bregni, Paraskevas Gkolfakis, Thomas Guiot, Andrea Pretta, et al.
Clinical Colorectal Cancer, 2021
Targeted agents in older patients with gastrointestinal cancers – An overview
Ana Raquel Monteiro, Rita Saúde Conde, Raquel Basto, Francesco Sclafani, Amélie Deleporte, et al.
Journal of Geriatric Oncology, 2021
Editorial: Radioembolization for metastatic colorectal cancer: Towards maturity, at last?
Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2021
Anal squamous cell carcinoma: Standards of care, new data and ongoing clinical trials
Emilio Francesco Giunta, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2021
Editorial introductions
Current Opinion in Oncology, 2021
The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis
Deborah J. Repullo, Sandrine Barbois, Daniel Leonard, Ali Bohlok, Estelle T. Van den Audenaeren, et al.
European Journal of Surgical Oncology, 2021
Fortnightly or fractionated weekly docetaxel–cisplatin–5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, Stéphane Holbrechts, Thierry Delaunoit, et al.
Cancer Medicine, 2021
The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases - Belgian Group for Digestive Oncology (BGDO)
Ali BOHLOK, Ivan DURAN DERIJCKERE, Hugues AZEMA, Valerio LUCIDI, Sophie VANKERCKHOVE, et al.
Annals of Hepato Biliary Pancreatic Surgery, 2021
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
E.F. Giunta, G. Bregni, A. Pretta, A. Deleporte, G. Liberale, et al.
Cancer Treatment Reviews, 2021
Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases
Ali Bohlok, Ivan Duran Derijckere, Hugues Azema, Valerio Lucidi, Sophie Vankerckhove, et al.
Journal of Surgical Oncology, 2021
Buschke-löwenstein tumor in a human immunodeficiency virus-positive patient: A case report and short literature review
V Ledouble, F Sclafani, A Hendlisz, M Gomez Galdon, G Liberale
Acta Gastro Enterologica Belgica, 2021
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
Christelle Bouchart, Jean-Luc Engelholm, Jean Closset, Julie Navez, Patrizia Loi, et al.
Therapeutic Advances in Medical Oncology, 2021
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
Giacomo Bregni, Caroline Vandeputte, Andrea Pretta, Chiara Senti, Elena Trevisi, et al.
Acta Oncologica, 2021
Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
Antoine El Asmar, Melissa Bendavides, Michel Moreau, Alain Hendlisz, Amélie Deleporte, et al.
World Journal of Surgical Oncology, 2020
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer
Silvia Camera, Amélie Deleporte, Giacomo Bregni, Elena Trevisi, Andrea Pretta, et al.
Clinical Colorectal Cancer, 2020
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
Ali Bohlok, Peter Vermeulen, Sophia Leduc, Emily Latacz, Lara Botzenhart, et al.
Npj Breast Cancer, 2020
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel
Giacomo Bregni, Tiberio Sticca, Silvia Camera, Tugba Akin Telli, Ligia Craciun, et al.
Acta Oncologica, 2020
Treatment compliance in early-stage anal cancer
A. Pretta, E. Trevisi, G. Bregni, A. Deleporte, A. Hendlisz, et al.
Annals of Oncology, 2020
Fat density is a novel prognostic marker in patients with esophageal cancer
Maëlle Anciaux, André Van Gossum, Cynthia Wenglinski, Lieveke Ameye, Thomas Guiot, et al.
Clinical Nutrition Espen, 2020
Prognostic value of the pace of tumor progression as assessed by serial18 f-fdg pet/ct scan and liquid biopsy in refractory colorectal cancer: The coriolan trial
Silvia Camera, Tugba Akin Telli, Erwin Woff, Caroline Vandeputte, Pashalina Kehagias, et al.
Cancers, 2020
Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified delphi method
Acta Gastro Enterologica Belgica, 2020
Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer
Maelle Anciaux, Pieter Demetter, Roland De Wind, Maria Gomez Galdon, Sylvie Vande Velde, et al.
BMJ Open Gastroenterology, 2020
Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2020
Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
Khurum Khan, Stefano Cascinu, David Cunningham, Sun-Young Kim, Eiji Oki, et al.
Cancer Treatment Reviews, 2020
The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases
Ali Bohlok, Valerio Lucidi, Fikri Bouazza, Ali Daher, Desislava Germanova, et al.
World Journal of Surgical Oncology, 2020
Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials
Rafael Caparica, Marco Bruzzone, Georges El Hachem, Marcello Ceppi, Matteo Lambertini, et al.
Critical Reviews in Oncology Hematology, 2020
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors
Maria Alice Franzoi, Caroline Vandeputte, Daniel Eiger, Rafael Caparica, Mariana Brandão, et al.
Breast Cancer Research and Treatment, 2020
Personalized selective internal radiation therapy in liver metastasis of thyroid cancer with impaired liver function: A case report
Maxime Herchuelz, Gwennaëlle Marin, Ivan Duran Derijckere, Michaël Vouche, Philippe Delatte, et al.
Radiology Case Reports, 2020
Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: A rationale for combining selective internal radiation therapy (SIRT) and immunotherapy
Ligia Craciun, Roland de Wind, Pieter Demetter, Valerio Lucidi, Ali Bohlok, et al.
BMC Cancer, 2020
Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
Oncotarget, 2020
Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
G. Bregni, T. Akin Telli, S. Camera, A. Deleporte, L. Moretti, et al.
Cancer Treatment Reviews, 2020
The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastases
Ivan Duran Derijckere, Hugo Levillain, Ali Bohlok, Celine Mathey, Jonathan Nezri, et al.
Journal of Surgical Oncology, 2020
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
Tugba Akin Telli, Giacomo Bregni, Silvia Camera, Amelie Deleporte, Alain Hendlisz, et al.
Cancer Letters, 2020
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Christelle Bouchart, Julie Navez, Jean Closset, Alain Hendlisz, Dirk Van Gestel, et al.
Therapeutic Advances in Medical Oncology, 2020
Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines
G. Bregni, T. Akin Telli, S. Camera, C. Baratelli, L. Shaza, et al.
Cancer Treatment Reviews, 2020
Combining 18F-FDG PET/CT-based metabolically active tumor volume and circulating cell-free DNA significantly improves outcome prediction in chemorefractory metastatic colorectal cancer
Erwin Woff, Pashalina Kehagias, Caroline Vandeputte, Lieveke Ameye, Thomas Guiot, et al.
Journal of Nuclear Medicine, 2019
Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study
Hugo Levillain, Ivan Duran Derijckere, Lieveke Ameye, Thomas Guiot, Arthur Braat, et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, Eric Van Cutsem, Jean-Pascal H. Machiels, et al.
Biodrugs, 2019
PRODIGE 7 should be interpreted with caution
Gabriel Liberale, Lieveke Ameye, Alain Hendlisz
Acta Chirurgica Belgica, 2019
Adjuvant chemotherapy for rectal cancer: playing the devil’s advocate
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2019
Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma
Corentin Delhaye, Alain Hendlisz, Michael Vouche
Current Opinion in Oncology, 2019
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial
Françoise Rothé, Marion Maetens, Ghizlane Rouas, Marianne Paesmans, Marc Van den Eynde, et al.
BMC Cancer, 2019
Folfiri as second-line treatment of metastatic biliary tract cancer patients
Rafael Caparica, Adrien Lengelé, Winnie Bekolo, Alain Hendlisz
Autopsy and Case Reports, 2019
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: A post hoc analysis of two non-randomized phase II trials
Nicolas Charette, Caroline Vandeputte, Lieveke Ameye, Camille Van Bogaert, Jonathan Krygier, et al.
BMC Cancer, 2019
Validation of metabolically active tumor volume and total lesion glycolysis as 18 F-FDG PET/CT–derived prognostic biomarkers in chemorefractory metastatic colorectal cancer
Erwin Woff, Alain Hendlisz, Lieveke Ameye, Camilo Garcia, Tarek Kamoun, et al.
Journal of Nuclear Medicine, 2019
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies
Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Julien Taieb, Jens Ricke, et al.
Clinical Colorectal Cancer, 2018
The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade
Ali Bohlok, Alain Hendlisz, Fikri Bouazza, Maria Gomez Galdon, Jean Van de Stadt, et al.
International Journal of Colorectal Disease, 2018
The unbearable lightness of therapeutic algorithms in colorectal liver metastasis
Alain Hendlisz, Vincent Donckier
Current Opinion in Oncology, 2018
Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer
Laura Polastro, Georges El Hachem, Alain Hendlisz
Current Opinion in Oncology, 2018
Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
Clinical Nuclear Medicine, 2018
The concept of oligometastases in colorectal cancer: From the clinical evidences to new therapeutic strategies
Edouard Massaut, Ali Bohlok, Valerio Lucidi, Alain Hendlisz, Jean A. Klastersky, et al.
Current Opinion in Oncology, 2018
Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study
Mégane Lemaire, Valerio Lucidi, Fikri Bouazza, Georgios Katsanos, Bruno Vanderlinden, et al.
HPB, 2018
Celyad's novel CAR T-cell therapy for solid malignancies
Caroline Lonez, Alain Hendlisz, Leila Shaza, Philippe Aftimos, Michaël Vouche, et al.
Current Research in Translational Medicine, 2018
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multikinase inhibitor
Caroline Vandeputte, Pashalina Kehagias, Hakim El Housni, Lieveke Ameye, Jean-François Laes, et al.
Oncotarget, 2018
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, et al.
Journal of Clinical Oncology, 2018
90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer
Hugo Levillain, Ivan Duran Derijckere, Gwennaëlle Marin, Thomas Guiot, Michaël Vouche, et al.
Ejnmmi Research, 2018
Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma
Michael Vouche, Thierry Degrez, Fikri Bouazza, Philippe Delatte, Maria Gomez Galdon, et al.
World Journal of Hepatology, 2017
Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, et al.
BMJ Open, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, et al.
Lancet Oncology, 2017
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, et al.
European Journal of Cancer, 2017
The meaningness of colon cancer sidedness
Alain Hendlisz
Current Opinion in Oncology, 2017
Tackling immunomonitoring in gastrointestinal cancer
Maëlle Anciaux, Caroline Vandeputte, Alain Hendlisz
Current Opinion in Oncology, 2017
Dyspnea and cardia cancer, an unusual etiology
Revue Medicale De Bruxelles, 2017
Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?
Geneviève Veereman, Joan Vlayen, Jo Robays, Nicolas Fairon, Sabine Stordeur, et al.
Critical Reviews in Oncology Hematology, 2017
Accuracy of FDG-PET/CT in colorectal peritoneal carcinomatosis: Potential tool for evaluation of chemotherapeutic response
GABRIEL LIBERALE, CÉLINE LECOCQ, CAMILO GARCIA, KRISTOF MUYLLE, ANGÉLIQUE COVAS, et al.
Anticancer Research, 2017
Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer
Eleonora Farinella, Adonis Safar, Haydar A. Nasser, Fikri Bouazza, Gabriele Liberale, et al.
Journal of Surgical Oncology, 2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
Erwin Woff, Alain Hendlisz, Camilo Garcia, Amelie Deleporte, Thierry Delaunoit, et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2016
Too little benefit for too much toxicity: Rethinking the adjuvant development model in colon cancer
Alain Hendlisz, Harry Bleiberg
Current Opinion in Oncology, 2016
Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer
Alexander Hamm, Hans Prenen, Wouter Van Delm, Mario Di Matteo, Mathias Wenes, et al.
Gut, 2016
Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases
Valerio Lucidi, Alain Hendlisz, Jean-Luc Van Laethem, Vincent Donckier
World Journal of Gastroenterology, 2016
In Deciphering the Future of Adjuvant Treatment in Colon Cancer, the Journey Matters More than the Achievements
Alain Hendlisz, Francesco Puleo, Amelie Deleporte, Leila Shaza, Nicolas Charette
Current Colorectal Cancer Reports, 2016
Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: Proof of concept
Minerva Chirurgica, 2016
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
E Elez, A Hendlisz, T Delaunoit, J Sastre, A Cervantes, et al.
British Journal of Cancer, 2016
A first-in-human phase i and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal, A. Awada, T. R. J. Evans, S. Dueland, A. Hendlisz, et al.
Cancer Chemotherapy and Pharmacology, 2015
The prognostic significance of metabolic response heterogeneity in metastatic colorectal cancer
Alain Hendlisz, Amelie Deleporte, Thierry Delaunoit, Raphaël Maréchal, Marc Peeters, et al.
Plos One, 2015
Colorectal cancer: Ten years of illusion of progress but advances are on the horizon
Revue Medicale De Bruxelles, 2015
Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma
Fikri Bouazza
World Journal of Gastroenterology, 2015
Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma
Revue Medicale Suisse, 2015
Of art and science: Is personalized medicine getting personal enough?
Alain Hendlisz
Current Opinion in Oncology, 2015
Y90 radioembolization of colorectal cancer liver metastases: Response assessment by contrast-enhanced computed tomography with or without PET-CT guidance
Michael Vouche, Riad Salem, Frank H. Miller, Marc Lemort, Bruno Vanderlinden, et al.
Clinical Imaging, 2015
Chemotherapy treatment patterns and neutropenia management in gastric cancer
Ewa Kalinka-Warzocha, Javier Gallego Plazas, Laurent Mineur, Tomas Salek, Alain Hendlisz, et al.
Gastric Cancer, 2015
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
G. Veereman, J. Robays, L. Verleye, R. Leroy, C. Rolfo, et al.
Critical Reviews in Oncology Hematology, 2015
Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study [BMC Cancer, 13, (2013), 190]
Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, et al.
BMC Cancer, 2015
Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte, Nicolas Charette, Marianne Paesmans, et al.
BMJ Open, 2015
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: The CORIOLAN study
Amelie Deleporte, Marianne Paesmans, Camilo Garcia, Caroline Vandeputte, Marc Lemort, et al.
BMC Cancer, 2014
Erratum: Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres (Physics in Medicine and Biology (2008) 53 (6591-603))
Patrick Flamen, Bruno Vanderlinden, Philippe Delatte, Ghanem Ghanem, Lieveke Ameye, et al.
Physics in Medicine and Biology, 2014
In times of crisis, go liquid!
Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte
Current Opinion in Oncology, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, Adelaide Dousseau, Bengt Glimelius, et al.
European Journal of Cancer, 2014
Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
F. E. Stuurman, E. E. Voest, A. Awada, P. O. Witteveen, T. Bergeland, et al.
Investigational New Drugs, 2013
Editorial introductions
Current Opinion in Oncology, 2013
Academic versus industry-driven research in upper gastrointestinal cancer: Sinners and saints
Alain Hendlisz, Nicolas Charette, Ahmad Awada, Amélie Deleporte
Current Opinion in Oncology, 2013
Phase i study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A. H. Awada, H. Dumez, A. Hendlisz, P. Wolter, T. Besse-Hammer, et al.
Investigational New Drugs, 2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, et al.
BMC Cancer, 2013
Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy
Jacques-Antoine Maisonobe, Camilo A. Garcia, Hatem Necib, Bruno Vanderlinden, Alain Hendlisz, et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2013
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer
Irène Buvat, Hatem Necib, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden, et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study
Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, et al.
Journal of Clinical Oncology, 2012
Selective internal radiation therapy simulation using 99mTc-labelled macroaggregates of albumin and SPECT-CT
Patrick Flamen, Alain Hendlisz, Bruno Vanderlinden
European Journal of Cancer Supplement, 2012
The confusion around neuroendocrine tumors
Alain Hendlisz, Amélie Deleporte
Current Opinion in Oncology, 2012
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A. Hendlisz, V. Golfinopoulos, C. Garcia, A. Covas, P. Emonts, et al.
Annals of Oncology, 2012
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: A randomized multicentric phase II study
R. Maréchal, B. Vos, M. Polus, T. Delaunoit, M. Peeters, et al.
Annals of Oncology, 2012
Phase i trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
Ahmad Awada, Alain Hendlisz, Olaf Christensen, Chetan D. Lathia, Sylvie Bartholomeus, et al.
European Journal of Cancer, 2012
The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer
Charlotte Mouton, Alain Ronson, Darius Razavi, François Delhaye, Nina Kupper, et al.
Autonomic Neuroscience Basic and Clinical, 2012
New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel
J.-L. Van Laethem, C. Verslype, J.L. Iovanna, P. Michl, T. Conroy, et al.
Annals of Oncology, 2012
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: Results of a phase 1 trial
Ahmad Awada, Thierry Gil, Nicolas Whenham, Julie Van Hamme, Tatiana Besse-Hammer, et al.
Journal of Clinical Pharmacology, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumors
Marc Buyse, Emmanuel Quinaux, Alain Hendlisz, Vassilis Golfinopoulos, Christophe Tournigand, et al.
Journal of Clinical Oncology, 2011
Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging
Hatem Necib, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden, Patrick Emonts, et al.
Journal of Nuclear Medicine, 2011
Small cell carcinoma of the esophagus: A multicentre rare cancer network study
B. Vos, T. Rozema, R. C. Miller, A. Hendlisz, J. L. Van Laethem, et al.
Diseases of the Esophagus, 2011
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
Alain Hendlisz, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, et al.
Journal of Clinical Oncology, 2010
Current Opinion in Oncology: Editorial introductions
&NA;
Current Opinion in Oncology, 2010
A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients
Acta Gastro Enterologica Belgica, 2010
The unfulfilled promise of molecular diagnosis in colorectal cancer
Vassilis Golfinopoulos, Alain Hendlisz
Current Opinion in Oncology, 2010
State of the art: Radiolabeled microspheres treatment for liver malignancies
Amélie Deleporte, Patrick Flamen, Alain Hendlisz
Expert Opinion on Pharmacotherapy, 2010
Is tailored adjuvant treatment for colon cancer possible?
Marc Van den Eynde, Ahmad Awada, Alain Hendlisz
Clinical Colorectal Cancer, 2010
Editorial: Adjuvant trials design in colon cancer
Alain Hendlisz, Vassilis Golfinopoulos
Current Opinion in Oncology, 2009
Current Opinion in Oncology: Editorial introductions
Current Opinion in Oncology, 2009
Treatment of colorectal liver metastases: A review
M. Eynde, A. Hendlisz
Reviews on Recent Clinical Trials, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, et al.
Cancer, 2009
Therapeutic consequences of molecular biology advances in oncology
F Bauvet, A Awada, T Gil, A Hendlisz
Bulletin Du Cancer, 2009
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: A prospective dose finding phase I-II study
S. Laurent, E. Monsaert, T. Boterberg, A. Demols, I. Borbath, et al.
Annals of Oncology, 2009
The antiproliferative effect of somatostatin analogs: Clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours
Acta Gastro Enterologica Belgica, 2009
The potential role of targeted therapies in the management of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: The end of a story?
Acta Gastro Enterologica Belgica, 2009
Diagnostic pitfalls in digestive neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
The role of surgery and transplantation in neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Carcinoid heart disease - A hidden complication of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
Patrick Flamen, Bruno Vanderlinden, Philippe Delatte, Ghanem Ghanem, Lieveke Ameye, et al.
Physics in Medicine and Biology, 2008
Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: A review
Revue Medicale De Bruxelles, 2008
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer
Raphaël Maréchal, Anne Demols, France Gay, Viviane de Maertelaer, Marianna Arvanitaki, et al.
Pancreas, 2008
Recommendations for general surgeons facing incidental peritoneal carcinomatosis of colorectal origin
G. Liberale, M. Van Den Eynde, A. Hendlisz, I. El Nakadi
European Journal of Surgical Oncology, 2008
Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres
Marc Van den Eynde, Patrick Flamen, Issam El Nakadi, Gabriel Liberale, Philippe Delatte, et al.
Clinical Nuclear Medicine, 2008
Concomitant chemo-radiotherapy as standard therapy in limited-stage small-cell oesophageal cancer: A summary of 3 clinical cases and review of the literature
Acta Gastro Enterologica Belgica, 2008
Epidermoid carcinoma of the colon and rectum and paraneoplastic hypercalcemia
Acta Clinica Belgica, 2007
Editorial introductions
Current Opinion in Oncology, 2007
A therapeutic approach to perianal extramammary Paget's disease: Topical imiquimod can be useful to prevent or defer surgery
Medical Science Monitor, 2007
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg, Jeffrey W. Clark, Ahmad Awada, Malcolm J. Moore, Heike Richly, et al.
Oncologist, 2007
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, et al.
Journal of Clinical Oncology, 2007
Don't believe... check!!
Alain Hendlisz
Current Opinion in Oncology, 2007
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer
R. Maréchal, A. Demols, F. Gay, V. De Maertelaere, M. Arvanitaki, et al.
Oncology, 2007
Efficacy and side effects of target biological therapies
A. Awada, A. Hendlisz, M.-J. Piccart-Gebhart
Oncologie, 2006
Screening colorectal cancer: The selection of patients at risk
Revue Medicale De Bruxelles, 2006
Editorial introductions
Current Opinion in Oncology, 2006
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study
A Demols, M Peeters, M Polus, R Marechal, F Gay, et al.
British Journal of Cancer, 2006
Hepatic intra-arterial injection of Yttrium-loaded microspheres for Liver Metastasis secondary to colorectal cancer: Best soups are sometimes made from old recipies
Acta Gastro Enterologica Belgica, 2006
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases
Nathalie Baize, Béatrice Gerard, Harry Bleiberg, François Caroli-Bosc, Frédéric Berthier, et al.
Gastroenterologie Clinique Et Biologique, 2006
Colorectal cancer (CRC) screening using sigmoidoscopy followed by colonoscopy: A feasibility and efficacy study on a cancer institute based population
H. Bleiberg, P. Autier, F. Huet, A.M. Schrauwen, E. Staquet, et al.
Annals of Oncology, 2006
Molecular medicine: Are we, clinicians, becoming old-fashioned?
Alain Hendlisz
Current Opinion in Oncology, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, et al.
British Journal of Cancer, 2005
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
N PERSONENI, A HENDLISZ, J GALLEZ, M GALDON, D LARSIMONT, et al.
Seminars in Oncology, 2005
Oral fluoropyrimidines in colorectal cancer: A door open to the future?
Acta Gastro Enterologica Belgica, 2004
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: An easy-to-use and well-tolerated combination
T. Delaunoit, R. Maréchal, A. Hendlisz, P. Eisendrath, H. Legendre, et al.
Anti Cancer Drugs, 2004
New anticancer agents and therapeutic strategies in development for solid cancers: A clinical perspective
Ahmad Awada, Max Mano, Alain Hendlisz, Martine Piccart
Expert Review of Anticancer Therapy, 2004
Prognostic stratification of Dukes B colon cancer by a neoglycoprotein.
Hugues Legendre, Christine Decaestecker, Max Gbenou, Nathalie Nagy, Alain Hendlisz, et al.
International Journal of Oncology, 2004
Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers
Hugues Legendre, Christine Decaestecker, Nathalie Nagy, Alain Hendlisz, Max-Peter Schüring, et al.
Modern Pathology, 2003
Advanced colorectal cancer treatment in Europe: What have we achieved?
Harry Bleiberg, Alain Hendlisz
Anti Cancer Drugs, 2002
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas
F.X Caroli-Bosc, J.L Van Laethem, P Michel, F Gay, A Hendlisz, et al.
European Journal of Cancer, 2001
Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer
B Gerard, H Bleiberg, D Van Daele, Th Gil, A Hendlisz, et al.
Anti Cancer Drugs, 1998
Importance of radiotherapy for gastric cancer
Bulletin Du Cancer, 1997
Non-surgical treatment of cancer of the pancreas
Journal De Chirurgie, 1997
Surveillance postopératoire des cancers colo-rectaux
Revue Du Praticien, 1996
Diagnosis and Treatment of Gastric Cancer
Alain Hendlisz, Harry Bleiberg
Drugs, 1995
Spinal epidural abscess after endoscopic treatment for chronic pancreatitis
Alain Hendlisz, Françoise Rypens, France Gay, André Vancossum, Michel Cremer
Pancreas, 1995

Alain Hendlisz

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS